• Skip to primary navigation
  • Skip to main content

SAAMnow

Scientists Advancing Affordable Medicines

  • Upcoming Events
    • 2022 Value Added Medicines Week
  • Past Workshops
    • 2022 Spring Scientific Workshop
    • 2019 Fall Scientific Workshop
    • 2019 Spring Scientific Workshop
    • 2018 Annual Scientific Workshop
  • Past Webinars
    • Challenges and Issues in Meeting Regulatory Requirements for In Vitro Dissolution Testing 
    • Secrets to Successful Pre-IND Meetings for 505(b)(2) NDA Drug Development
    • In Silico Modeling Methods for Generic Drug Products: Applications and Expectations
    • 505(b)(2) Webinar Series: Session 3
    • 505(b)(2) Webinar Series: Session 2
    • 505(b)(2) Webinar Series: Session 1
  • About Us
  • Join
  • Contact Us

505(b)(2) Webinar Series: Session 2

The first two sessions (May 13th and May 20th) will focus on the 505(b)(2) NDA pathway for US FDA submission, and will feature speakers that participated in SAAMnow’s successful workshop on Demystifying 505(b)(2) Development: Navigating the Scientific, Regulatory, Legal, and Business Complexities (October 16-18, 2019, Philadelphia, PA). The workshop highlighted the diversity, simplicity and complexity of the 505(b)(2) application process, and via these webinars we want to continue to fill the basic educational gap in understanding and characterizing the 505(b)(2) pathway by giving participants an opportunity to learn from experts in this field.

Webinar Session 2: Intellectual property and regulatory considerations for filing a 505(b)(2) NDA

Presenter 1: Barbara Binzak Blumenfeld, PhD, JD, MA, Attorney at Law, Buchanan Ingersoll & Rooney PC:  Optimizing Your 505(b)(2) FDA Regulatory Strategy

Presenter 2: Matthew Fedowitz, JD, Attorney at Law, Buchanan Ingersoll & Rooney PC: Current Strategies for Obtaining, Maneuvering Around and Enforcing IP Involving 505(b)(2) Products

Areas Covered:

  • Patent certification and intellectual property considerations for 505(j) and 505(b)(2) applications, including identifying Listed Drug and patents covering Listed Drug, developing your patent strategy and portfolio for Orange Book listed patents and non-Orange Book patents, navigating the appropriate certification to make, and timing of your 505(b)(2) NDA.
  • Filing a 505(b)(2) NDA application: regulatory issues and approval requirements.
  • Strategic considerations for a 505(b)(2) NDA, including business, development and marketing factors, and critical questions to consider in the scientific, medical, regulatory and market areas.

For more information about SAAMnow, contact us below.

Contact Us

Copyright © 2023 · SAAMnow